Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.8961 per EA under NDC 67877062460. Its NADAC has been published 50 times since Dec 3, 2025.

FDA first approved this application on Mar 11, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 110 MG CP

Dabigatran Etexilate
$0.8961per EA

Strength

110 mg/1

NDC

67877062460

Classification

Generic

Dosage Form

CAPSULE, COATED PELLETS

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208040

FDA Approved

3/11/2020

TE Code

AB

On Market Since

9/12/2025

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 50 times since Dec 3, 2025, and over the history we have for it it has declined 44.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8961 per EA
All-time high$1.6053 (Dec 10, 2025)
All-time low$0.8961 (Oct 21, 2026)
52-week high$1.6053
52-week low$0.8961
Median price$0.9460
Average price$1.0563
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked50
Tracking sinceDec 3, 2025

Price History

1W

0.0%

1M

-4.4%

3M

-8.0%

6M

-2.6%

1Y

N/A

3Y

N/A

5Y

N/A

All

-44.2%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Ascend Laboratories, LLC, is $0.8961 per EA (NDC 67877062460), effective Nov 11, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 44.2%. It has been tracked across 50 weekly CMS publications since Dec 3, 2025.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Dec 3, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.8961 (Oct 21, 2026) to a high of $1.6053 (Dec 10, 2025), with a median of $0.9460 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, but none are currently priced below it.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 67877062460) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.